Articles related to DRUG SHORTAGES

The introduction of lisdexamfetamine, a generic for Vyvanse, initially showed promise in increasing access to ADHD treatment. However, it too has fallen into shortage, highlighting the ongoing challenges in meeting patient demand.

The recent recall of Zenzedi 30 mg tablets due to contamination stresses the importance of meticulous medication management and awareness of the broader challenges in ADHD treatment availability and safety.

The stimulant crisis is affecting ADHD treatment across the board; Dr. Greg Mattingly offers crucial insights into navigating this challenging landscape. Learn about alternative treatment options to better serve your patients.

The DEA and FDA are addressing the current prescription stimulant shortage, emphasizing both the importance of patient access and the need for responsible prescribing. Stay informed on the latest updates and consider alternative treatments where appropriate.

The chemotherapy shortage in the US is a pressing issue that demands a reevaluation of health policies. Dive deeper into the potential strategies for mitigating its impact, from creating a market for high-quality generics to convening a multi-stakeholder task force.

The potential shortage of Saxenda (liraglutide) through 2023 underscores the importance of monitoring the availability of this weight management drug. Physicians should be aware of this situation and consider alternative options if necessary.